Angiodynamics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Angiodynamics Inc (ANGO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Angiodynamics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 324M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (+0.0% annualized vs trailing 12 months).
- Scale: Angiodynamics Inc ranks #83 of 246 companies by market capitalization in the Medical Equipment & Supplies industry, holding 0.0% of industry market cap.
- Peer revenue share: Angiodynamics Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.51M compares with $0.39M for the peer group (1.3x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ANGO Sales vs. its Competitors, Q1 2026
Angiodynamics Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Medical Equipment & Supplies industry grew revenue 15.0% year over year, combined, vs 8.1% for Angiodynamics Inc. Angiodynamics Inc's share of combined industry revenue moved from 0.07% to 0.07%, a gain of 0.00 percentage points.
Angiodynamics Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Angiodynamics Inc | No | Yes | No | No |
| Competitors combined (37) | ||||
| High-Confidence Competitors (14) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 87.50 % (7 of 8) | 75.00 % (6 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ANGO Stock Performance relative to its Competitors
ANGO Stock Performance relative to High-Confidence Competitors
ANGO Stock Performance relative to Similar-Size Competitors
ANGO Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Atricure Inc | 282.9% | Outperformed |
| 2 | Livanova Plc | 282.9% | Outperformed |
| 3 | Orchestra Biomed Holdings Inc | 282.9% | Outperformed |
| 4 | Flex Ltd | 282.9% | Outperformed |
| 5 | Icu Medical Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Angiodynamics Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Angiodynamics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Angiodynamics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Angiodynamics Inc | 499.64 | 323.78 |
| Johnson and Johnson | 629,008.98 | 97,929.00 |
| Abbott Laboratories | 175,598.31 | 45,134.00 |
| Medtronic Plc | 119,552.85 | 37,542.00 |
| Stryker Corp | 114,835.00 | 25,837.00 |
| Boston Scientific Corporation | 65,643.35 | 20,997.00 |
| SUBTOTAL | 1,313,869.17 | 316,075.81 |
Sign in to see all competitors of Angiodynamics Inc .
Sources: Angiodynamics Inc's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Angiodynamics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Angiodynamics Inc's Competitors Named by the Company
Competitive relationships identified from Angiodynamics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Inari Medical | Company report | 85% |
| Boston Scientific Corporation | Company report | 85% |
| Medtronic | Company report | 85% |
| TeleFlex Medical | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Varian Medical Systems | Company report | 85% |
| Avinger Inc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| EDAP TMS | Company report | 85% |
| Merit Medical | Company report | 85% |
| Siemens Healthineers | Company report | 85% |
| Terumo Medical Corporation | Company report | 85% |
| Medical Components, Inc. (MedComp) | Company report | 85% |
| Stryker Corporation | Company report | 85% |
| Penumbra, Inc. | Company report | 85% |
| Total Vein Systems | Company report | 85% |
| Cook Medical | Company report | 85% |
| Profound Medical | Company report | 85% |
| Becton Dickinson | Company report | 85% |
| Philips 8 Healthcare | Company report | 85% |
| Philips Healthcare | Company report | 85% |
| Smiths Group plc | Company report | 85% |
| Smiths Medical | Company report | 85% |
| BD Medical Technology | Company report | 85% |
| Icu Medical Inc | Company report | 85% |
| Renovorx Inc | Company report | 85% |
| Flex Ltd | Company report | 85% |
| Atrion Corporation | Company report | 85% |
| Encision Inc | Company report | 85% |
| Utah Medical Products Inc | Company report | 85% |
| Procept Biorobotics Corporation | Company report | 85% |
| Abiomed Inc | Company report | 85% |
| Ir med Inc | Company report | 85% |
| Vaso Corporation | Company report | 85% |
| Edwards Lifesciences Corporation | Company report | 85% |
| Shockwave Medical Inc | Company report | 85% |
| Lemaitre Vascular Inc | Company report | 85% |
| Atricure Inc | Company report | 85% |
| Livanova Plc | Company report | 85% |
| Streamex Corp | Company report | 85% |
Company report basis, confidence, active dates and source counts for Angiodynamics Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from Angiodynamics Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.
Angiodynamics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Angiodynamics Inc | Med Device 50.67 % |
| Johnson and Johnson | Oncology 29.26 % |
| Abbott Laboratories | Diabetes Care 17.78 % |
| Medtronic Plc | CARDIOVASCULAR 38.34 % |
| Stryker Corp | MedSurg and Neurotechnology 55.02 % |
| Boston Scientific Corporation | Cardiovascular 67.31 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Angiodynamics Inc .
Angiodynamics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Angiodynamics Inc | 500 | 512,316 | -52,114 |
| Johnson and Johnson | 629,009 | 695,518 | 149,411 |
| Abbott Laboratories | 175,598 | 392,470 | 54,574 |
| Medtronic Plc | 119,553 | 395,179 | 55,463 |
| Stryker Corp | 114,835 | 461,375 | 66,589 |
| Boston Scientific Corporation | 65,643 | 355,881 | 62,186 |
| PEERS TOTAL | 1,313,370 | 389,462 | 51,084 |
Sign in to see all peers for Angiodynamics Inc .
Angiodynamics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Angiodynamics Inc | United States 87.83 % |
| Johnson and Johnson | United States 57.42 % |
| Abbott Laboratories | Non-US 61.62 % |
| Medtronic Plc | United States 49.83 % |
| Stryker Corp | United States 75.26 % |
| Boston Scientific Corporation | United States 63.11 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Angiodynamics Inc .
Angiodynamics Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 220 companies in Angiodynamics Inc's industry classification, broader than the peer set above. Market cap in millions of $.Angiodynamics Inc ranks #83 of 220 companies by market capitalization in its industry, holding 0.04 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 597, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 151,974 | 13.32 % |
| 2 | Medtronic Plc | 122,252 | 10.71 % |
| 3 | Stryker Corp | 116,723 | 10.23 % |
| 4 | 3m Company | 88,262 | 7.73 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Becton Dickinson And Company | 1,234 | 5.2% |
| 7 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 8 | Resmed Inc | 1,234 | 5.2% |
| 9 | Alcon inc | 1,234 | 5.2% |
| 10 | Dexcom Inc | 1,234 | 5.2% |
| 83 | Angiodynamics Inc | 502 | 0.04 % |
Market cap and industry share for the rest of Angiodynamics Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-10-21.
Angiodynamics Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 78 | Anteris Technologies Global Corp | 621 | 7.50 % |
| 79 | Mimedx Group Inc | 617 | -38.15 % |
| 80 | Delcath Systems Inc | 593 | 30.56 % |
| 81 | Orthopediatrics Corp | 572 | 35.18 % |
| 82 | Tactile Systems Technology Inc | 1,234 | 12.3% |
| 83 | Angiodynamics Inc | 502 | 2.28 % |
| 84 | Sight Sciences Inc | 1,234 | 12.3% |
| 85 | Cerus Corporation | 1,234 | 12.3% |
| 86 | Neuropace Inc | 1,234 | 12.3% |
| 87 | Avita Medical Inc | 1,234 | 12.3% |
| 88 | Strata Critical Medical Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Angiodynamics Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-10-21. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Angiodynamics Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (331 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 55.92 % | 49.59 % (avg) | +6.3 pp |
| Operating Margin | -11.30 % | industry median | -8.9 pp |
| EBITDA Margin | 8.60 % | -6.61 % (avg) | +15.2 pp |
| Capital Intensity (Capex / Revenue) | - | 7.55 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Angiodynamics Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (331 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 35.6x | - |
| EV / EBITDA | 20.9x | 17.7x | +3.2x |
| P/B | 3.6x | 4.5x | -0.9x |
| Return on Equity | -19.06 % | industry aggregate | -0.91 % |
| Return on Invested Capital | -9.90 % | -3.24 % (avg) | -6.66 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Angiodynamics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | -0.69 % | -14.82 % | -7.65 % | 11.87 % | 8.13 % | 0.05 % | -13.30 % | 7.45 % |
| Operating Margin | 4.25 % | -6.12 % | -63.74 % | -13.88 % | -10.10 % | -2.39 % | -83.85 % | -10.65 % |
| Return on Invested Capital | 1.21 % | -1.38 % | -16.12 % | -4.43 % | -3.62 % | -0.91 % | -55.00 % | -8.36 % |
| P/E | 25.2x | 10.5x | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Angiodynamics Inc's Strategic Group Map
Every company in Angiodynamics Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Angiodynamics Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Angiodynamics Inc's BCG Growth-Share Matrix
Relative market share (vs Angiodynamics Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Angiodynamics Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 9.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Angiodynamics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 597 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Angiodynamics Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Angiodynamics Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Angiodynamics Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Angiodynamics Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Angiodynamics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Operating margin 8.9 points below the industry median.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Angiodynamics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Angiodynamics Inc | 0.66 | 2.28 | - |
| Johnson and Johnson | 0.37 | 1.05 | 0.60 |
| Abbott Laboratories | 0.47 | 1.60 | 0.35 |
| Medtronic Plc | 0.15 | 2.10 | 0.57 |
| Stryker Corp | 0.48 | 1.99 | 0.68 |
| Boston Scientific Corporation | 0.25 | 1.54 | 0.47 |
Sign in to see all peers for Angiodynamics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Angiodynamics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Angiodynamics Inc | Q3 2026 | +8.1 % | - |
| Johnson and Johnson | Q2 2026 | +6.6 % | -0.1 % |
| Abbott Laboratories | Q1 2026 | +7.8 % | -18.7 % |
| Medtronic Plc | Q2 2026 | +13.7 % | +41.3 % |
| Stryker Corp | Q2 2026 | +9.4 % | +44.3 % |
| Boston Scientific Corporation | Q2 2026 | +7.5 % | +13.8 % |
| PEERS TOTAL | +8.8 % | +10.9 % |
Sign in to see all peers for Angiodynamics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Angiodynamics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Angiodynamics Inc | Q3 2026 | -0.4 % | +103.0 % |
| Johnson and Johnson | Q2 2026 | +5.5 % | +26.7 % |
| Abbott Laboratories | Q1 2026 | +9.4 % | -17.6 % |
| Medtronic Plc | Q2 2026 | +13.8 % | -0.2 % |
| Stryker Corp | Q2 2026 | -4.1 % | +10.4 % |
| Boston Scientific Corporation | Q2 2026 | -2.6 % | +24.2 % |
Sign in to see all peers for Angiodynamics Inc .
Angiodynamics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Angiodynamics Inc | - | - | - |
| Johnson and Johnson | 10.60% | 13.30% | 25.74% |
| Abbott Laboratories | 6.87% | 8.15% | 12.09% |
| Medtronic Plc | 5.71% | 6.46% | 10.64% |
| Stryker Corp | 7.89% | 8.80% | 16.36% |
| Boston Scientific Corporation | 8.34% | 9.91% | 14.77% |
Sign in to see all peers for Angiodynamics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Angiodynamics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Angiodynamics Inc | - | 1.54 |
| Johnson and Johnson | 29.84 | 6.42 |
| Abbott Laboratories | 28.00 | 3.89 |
| Medtronic Plc | 273.62 | 3.18 |
| Stryker Corp | 30.83 | 4.44 |
| Boston Scientific Corporation | 18.04 | 3.13 |
| PEERS AVERAGE | 31.75 | 4.16 |
Sign in to see all peers for Angiodynamics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.